|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 利拉鲁肽与格列美脲在单药治疗2型糖尿病中的比较(LEAD-3 Mono):一项随机、双盲、平行分组、52周的Ⅲ期临床试验显示文摘背景 2型糖尿病新的治疗策略,需要针对胰岛素-葡萄糖的相互作用,且同时要降低体重增加和发生低血糖的风险。本文作者旨在调查利拉鲁肽单药治疗2型糖尿病的安全性与有效性。
方法 采用双盲、双模拟、治疗一对照、平行分组的研究,746例早期2型糖尿病患者被随机分配到1次/d利拉鲁肽组[1.2mg(n=251)或1.8mg(n=247)]或格列美脲8mg组(n=248),分别治疗52周。主要结局指标为糖化血红蛋白(HbA1c)的改变程度。采用意向性治疗进行分析。该试验在ClinicalTrials.gov网站的注册编码为NTC00294723.
结果52周时,格列美脲组HbA,。下降了0.51%(s=1.20),而利拉鲁肽1.2mg组下降了0.84%(s=1.23)(差值为-0.33.95%CI-0.53~-0.13;P=0.0014),利拉鲁肽1.8mg组下降了1.14%(S=1.24)(差值为-062,95%CI-0.83—-0.42;P〈0.0001)。利拉鲁肽1.2mg组和1.8mg组各有5例和1例患者因呕吐停止治疗,而格列美脲组未出现这种情况。
结论 利拉鲁肽作为2型糖尿病的初始治疗药物安全有效,与格列美脲相比更能降低HbA1c以及体重、血压和低血糖的发生率。 | Alan Garber Robert Henry Robert Rather Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvero-Alvarez Paula M Hale, Milan Zdravkovic Bruce Bode 邓斌(译) | 2009 | 世界临床医学2009，，6： | 5 |
| 2 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial显示文摘 | Alan Garber Robert Henry Robert Ratner Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvera-Alvarez Paula M Hale Milan Zdravkovic Bruce Bode | 2009 | The Lancet2009，，9662： | 2 |
| 3 | Liralutide versus glimepiridemonotherapy for type 2 diabetes(LEAD-3 Mono):a radomised,52-week,phase,III,double-blind,parallel-treatment trial显示文摘 | Garber A Henry R Ratner R | 2009 | Lancet2009，373，9662： | 1 |
| 4 | Type 2 diabetes and cardiovascular risk factors显示文摘 | Sharma MD Farmer JA Garber A | 2011 | Current Med Res Opinion2011，27，3： | 1 |
| 5 | Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 mono):randomised,52-week,phaseⅢ,double-blind,parallel-treatment trial显示文摘 | Garber A Henry R Ratner R | 2009 | Lancet2009，373，9662： | 1 |
| 6 | Foraging strategies among living primates显示文摘 | Garber P A | | 0，，01： | 1 |
| 7 | American Associa- tion of Clinical Endocrinologists' comprehensive diabetes manage- ment algorithm 2013 consensus statement-executive summary显示文摘 | Garber A J Abrahamson M J Barzilay J I | 2013 | Endocr Praet2013，19，3： | 1 |
| 8 | Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters 显示文摘 | Cliffe A R Garber D A Knipe D M | 2009 | J Virol2009，83，16： | 1 |
| 9 | Meta-analysis demonstrates that Liraglutide,a once-daily human GLP-1 analogue,significantly reduces lipids ang other markers of cardiovascular risk in type 2 diabetes显示文摘 | Plutzky J Garber A Toft AD | 2009 | Diabetologia2009，52，1： | 1 |
| 10 | GLP-1R agonist therapy for diabetes:benefits and potential risks显示文摘 | Samson SL Garber A | 2013 | Curr Opin Endocrinol Diabetes Obes2013，20，2： | 1 |
| 11 | Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes显示文摘 | Plutzky J Garber A Toft AD | 2009 | Diabetologia2009，52，1： | 1 |
| 12 | Resolution of mixed human DNA samples using mitochondrial DNA sequence variants显示文摘 | Walker J A Garber R K Hedges D J | 2004 | Anal Biochem2004，325，1： | 1 |
| 13 | AmericanAs- sociation of Clinical Endocrinologists comprehensive dia- betesmanagement algorithm 2013 consensus statementexecu- tivesummaryl显示文摘 | Garber A J Abrahamson M J Barzilayj I | 2013 | Endocr Pract2013，47，19： | 1 |
| 14 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3Mono) : a randomized, 52-week, phase III, double-blind,parallel-treatment trial 显示文摘 | Garber A Henry R Rather R | 2009 | J Lancet2009，373，9662： | 1 |
| 15 | Oral poly(ADP-ribose) polymer- ase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial 显示文摘 | Tutt A Robson M Garber JE | 2010 | Lancet2010，376，9737： | 1 |
| 16 | Attainment of glycaemic goals in type 2 diabetes with once -, twice -, or thrice - daily dosing with biphasic insulin aspart 70/30 显示文摘 | GARBER A J WAHLEN J WAHL T | 2006 | Diabetes Obes Metab2006，8，1： | 1 |
| 17 | Two-stage versus one-stage-is there really a controversy 显示文摘 | GARBER D A SALAMA H S ALAMA M A | 2001 | J Periodentol2001，72，3： | 1 |
| 18 | Meta-analysis demonstrates that liraglutide,a once-daily human GLP-1 analogue,significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes显示文摘 | Plutzky J Garber A Toft AD | 2009 | Diabetologia2009，52，1： | 1 |
| 19 | Theory of the temperature dependence of second-order elastic constants in cubic materials显示文摘 | GARBER J A GRANATO A V | 1975 | Phys Rev B1975，11，： | 1 |
| 20 | Feasibility of immunodiagnostic devices for the detection of ricin, amanitin, and T-2 toxin in food显示文摘 | GARBER E A EPPLEY R M STACK M E | 2005 | Journal of Food Protection2005，68，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员